Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
L-Phenylalanine 500mg capsules
0913445A0AAAGAG
|
Pdr disc/non ACBS single L-amino acid supplement (0913445) | Pdr disc/non ACBS single L-amino acid supplement (0913445) | Nutrition and Blood | 33 |
|
Citrulline powder
0913445A0AAADAD
|
Pdr disc/non ACBS single L-amino acid supplement (0913445) | Pdr disc/non ACBS single L-amino acid supplement (0913445) | Nutrition and Blood | 4 |
|
L-arginine powder
0913445A0AAACAC
|
Pdr disc/non ACBS single L-amino acid supplement (0913445) | Pdr disc/non ACBS single L-amino acid supplement (0913445) | Nutrition and Blood | 1 |
|
Alanine powder
0913445A0AAABAB
|
Pdr disc/non ACBS single L-amino acid supplement (0913445) | Pdr disc/non ACBS single L-amino acid supplement (0913445) | Nutrition and Blood | No data available |
|
Cystine oral powder
0913445A0AAAHAH
|
Pdr disc/non ACBS single L-amino acid supplement (0913445) | Pdr disc/non ACBS single L-amino acid supplement (0913445) | Nutrition and Blood | No data available |
|
Generic Adamin-G oral powder 5g sachets
0913445A0AAAAAA
|
Pdr disc/non ACBS single L-amino acid supplement (0913445) | Pdr disc/non ACBS single L-amino acid supplement (0913445) | Nutrition and Blood | No data available |
|
Lysine powder
0913445A0AAAEAE
|
Pdr disc/non ACBS single L-amino acid supplement (0913445) | Pdr disc/non ACBS single L-amino acid supplement (0913445) | Nutrition and Blood | No data available |
|
Ornithine powder
0913445A0AAAFAF
|
Pdr disc/non ACBS single L-amino acid supplement (0913445) | Pdr disc/non ACBS single L-amino acid supplement (0913445) | Nutrition and Blood | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.